Literature DB >> 23483799

Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.

Guan-Min Lai1, Sheng-Lei Yan, Cheng-Shyong Chang, Chien-Yu Tsai.   

Abstract

Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with chronic HBV infection receiving cytotoxic or immunosuppressive chemotherapy. Imatinib mesylate and nilotinib are selective Bcr/Abl tyrosine kinase inhibitors, which are now widely used in the treatment of patients with chronic myeloid leukemia. Although HBV reactivation induced by imatinib mesylate has been reported, nilotinib-related HBV reactivation has not been reported in the English literature. We report here 2 cases of HBV reactivation in chronic myeloid leukemia patients receiving imatinib mesylate and a novel case of nilotinib related HBV reactivation.

Entities:  

Keywords:  Chronic myeloid leukemia; Hepatitis B virus; Imatinib mesylate; Nilotinib; Tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2013        PMID： 23483799      PMCID： PMC3587491          DOI： 10.3748/wjg.v19.i8.1318

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  24 in total

1.  Histological features of acute hepatitis after imatinib mesylate treatment.

Authors:  C James; H Trouette; G Marit; P Cony-Makhoul; F-X Mahon
Journal:  Leukemia       Date:  2003-05       Impact factor: 11.528

2.  Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis.

Authors:  K Ohyashiki; Y Kuriyama; A Nakajima; T Tauchi; Y Ito; H Miyazawa; Y Kimura; H Serizawa; Y Ebihara
Journal:  Leukemia       Date:  2002-10       Impact factor: 11.528

3.  Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports.

Authors:  S G Kim; J M Chun; R Jin; J Y Kim; D I Won; Y J Hwang
Journal:  Transplant Proc       Date:  2010-04       Impact factor: 1.066

Review 4.  Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: a review of the problem.

Authors:  R Liang; G K Lau; Y L Kwong
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

Review 5.  Hepatitis B virus (HBV) reactivation after cytotoxic or immunosuppressive therapy--pathogenesis and management.

Authors:  L Xunrong; A W Yan; R Liang; G K Lau
Journal:  Rev Med Virol       Date:  2001 Sep-Oct       Impact factor: 6.989

6.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.

Authors:  W Yeo; P K Chan; S Zhong; W M Ho; J L Steinberg; J S Tam; P Hui; N W Leung; B Zee; P J Johnson
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

Review 7.  Advances in the biology and therapy of patients with chronic myeloid leukaemia.

Authors:  Elias Jabbour; Carmen Fava; Hagop Kantarjian
Journal:  Best Pract Res Clin Haematol       Date:  2009-09       Impact factor: 3.020

Review 8.  Management of viral hepatitis in hematologic malignancies.

Authors:  Roberto J Firpi; David R Nelson
Journal:  Blood Rev       Date:  2008-03-14       Impact factor: 8.250

9.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.

Authors:  B J Druker; S Tamura; E Buchdunger; S Ohno; G M Segal; S Fanning; J Zimmermann; N B Lydon
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640
View more
  27 in total

1.  Hepatitis B virus reactivation during immunosuppressive therapy: Appropriate risk stratification.

Authors:  Wai-Kay Seto
Journal:  World J Hepatol       Date:  2015-04-28

Review 2.  Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions.

Authors:  Rohit Loomba; T Jake Liang
Journal:  Gastroenterology       Date:  2017-02-20       Impact factor: 22.682

3.  Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

Authors:  Xiaoming Cheng; Takuro Uchida; Yuchen Xia; Regina Umarova; Chun-Jen Liu; Pei-Jer Chen; Anuj Gaggar; Vithika Suri; Marcus M Mücke; Johannes Vermehren; Stefan Zeuzem; Yuji Teraoka; Mitsutaka Osawa; Hiroshi Aikata; Keiji Tsuji; Nami Mori; Shuhei Hige; Yoshiyasu Karino; Michio Imamura; Kazuaki Chayama; T Jake Liang
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

4.  Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.

Authors:  Toshihiko Ando; Kensuke Kojima; Hiroshi Isoda; Yuichiro Eguchi; Takashi Honda; Masatoshi Ishigami; Shinya Kimura
Journal:  Int J Hematol       Date:  2015-04-05       Impact factor: 2.490

Review 5.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

6.  Reactivation of hepatitis B virus after withdrawal of erlotinib.

Authors:  N Bui; I Wong-Sefidan
Journal:  Curr Oncol       Date:  2015-12       Impact factor: 3.677

7.  Hepatitis B Virus Reactivation in the Setting of Immunosuppressive Drug Therapy.

Authors:  Jessica Su; Joseph K Lim
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-11

Review 8.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 9.  Prevention and management of hepatitis B virus reactivation in cancer patients.

Authors:  Ka-Shing Cheung; Wai-Kay Seto; Ching-Lung Lai; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2016-01-06       Impact factor: 6.047

Review 10.  Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.

Authors:  Bettina M Knoll; K Seiter
Journal:  Infection       Date:  2018-01-31       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.